X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ATH434
Therapeutic Area: Neurology Product Name: ATH434
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2021
Details:
ATH434 is the first of a new generation of small molecule drug candidates designed to block the accumulation and aggregation of α-synuclein.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ATH434
Therapeutic Area: Neurology Product Name: ATH434
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2020
Details:
Data from bioMUSE will also be used to inform patient selection in Alterity’s upcoming Phase 2 clinical trial of ATH434, its lead clinical candidate for the treatment of MSA.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
